A urothelial carcinoma drug developed by Jiangsu Hengrui Medicine's (SHA:600276) unit was included in the National Medical Products Administration's list of proposed breakthrough therapeutic products, according to a Shanghai Stock Exchange filing on Thursday.
The SHR-A2102 injection of subsidiary Shanghai Hengrui Medicine was included in the list after it passed the regulator's review, the Chinese pharmaceutical company said.
The company's shares rose 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments